Compare GSK Pharma with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs DISHMAN PHARMA - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA DISHMAN PHARMA GSK PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x 52.5 25.1 209.4% View Chart
P/BV x 11.1 3.3 330.3% View Chart
Dividend Yield % 1.4 0.7 215.6%  

Financials

 GSK PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
DISHMAN PHARMA
Mar-16
GSK PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs3,595374 960.2%   
Low Rs1,253129 972.1%   
Sales per share (Unadj.) Rs184.7197.8 93.4%  
Earnings per share (Unadj.) Rs26.321.2 124.0%  
Cash flow per share (Unadj.) Rs29.234.7 84.0%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %0.80.8 103.8%  
Book value per share (Unadj.) Rs126.3179.9 70.2%  
Shares outstanding (eoy) m169.4080.69 209.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x13.11.3 1,031.8%   
Avg P/E ratio x92.211.9 776.9%  
P/CF ratio (eoy) x83.17.2 1,146.9%  
Price / Book Value ratio x19.21.4 1,371.8%  
Dividend payout %76.19.4 806.5%   
Avg Mkt Cap Rs m410,62620,306 2,022.2%   
No. of employees `0005.00.8 598.3%   
Total wages/salary Rs m5,3725,355 100.3%   
Avg. sales/employee Rs Th6,306.719,252.7 32.8%   
Avg. wages/employee Rs Th1,083.16,459.5 16.8%   
Avg. net profit/employee Rs Th898.02,064.1 43.5%   
INCOME DATA
Net Sales Rs m31,28115,961 196.0%  
Other income Rs m1,023265 385.5%   
Total revenues Rs m32,30416,226 199.1%   
Gross profit Rs m6,0094,103 146.4%  
Depreciation Rs m4861,091 44.6%   
Interest Rs m6944 0.6%   
Profit before tax Rs m6,5402,334 280.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m2870-   
Tax Rs m2,373624 380.5%   
Profit after tax Rs m4,4541,711 260.3%  
Gross profit margin %19.225.7 74.7%  
Effective tax rate %36.326.7 135.8%   
Net profit margin %14.210.7 132.8%  
BALANCE SHEET DATA
Current assets Rs m20,06111,018 182.1%   
Current liabilities Rs m14,5439,517 152.8%   
Net working cap to sales %17.69.4 187.6%  
Current ratio x1.41.2 119.2%  
Inventory Days Days57110 51.4%  
Debtors Days Days1435 40.4%  
Net fixed assets Rs m14,34316,304 88.0%   
Share capital Rs m1,694161 1,049.6%   
"Free" reserves Rs m19,70412,907 152.7%   
Net worth Rs m21,39814,516 147.4%   
Long term debt Rs m24,189 0.0%   
Total assets Rs m39,11329,805 131.2%  
Interest coverage x1,091.03.5 31,432.0%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.80.5 149.3%   
Return on assets %11.48.9 128.0%  
Return on equity %20.811.8 176.6%  
Return on capital %31.917.5 182.1%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m5344,952 10.8%   
Fx outflow Rs m7,091697 1,017.7%   
Net fx Rs m-6,5574,255 -154.1%   
CASH FLOW
From Operations Rs m3,9942,786 143.3%  
From Investments Rs m-1,433-1,529 93.8%  
From Financial Activity Rs m-3,584-941 380.8%  
Net Cashflow Rs m-1,023316 -323.4%  

Share Holding

Indian Promoters % 0.0 61.4 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 3.7 275.7%  
FIIs % 23.8 12.7 187.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 22.1 69.7%  
Shareholders   102,036 46,261 220.6%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   SUN PHARMA  PROCTER & GAMBLE HEALTH  NOVARTIS  FULFORD INDIA  DR. REDDYS LAB  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Sep 19, 2019 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - AUROBINDO PHARMA COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS